THAR

FDA Feedback on TH104: Tharimmune's lead clinical asset, TH104 (nalmefene buccal film), received positive feedback from the FDA regarding its pharmacokinetic simulation modeling plan, which is crucial for advancing its development as a treatment for respiratory depression caused by opioids.

Operational Milestones: The company is set to initiate a comprehensive Chemistry, Manufacturing, and Controls (CMC) plan to ensure the quality and consistency of TH104, marking a significant step towards advanced clinical development and commercial readiness.

Simulation Analysis Findings: The pharmacokinetic simulation analysis indicated that TH104 could provide rapid onset of protection within 30 minutes and sustained protection for about 24 hours, offering a potential advantage over existing treatments like naloxone.

Digital Asset Strategy: In addition to its biotechnology efforts, Tharimmune is developing a digital asset treasury strategy utilizing the Canton Coin to enhance the digitization of traditional financial markets through the Canton Network.

U.S. Stock Market Performance: The Dow Jones fell by 0.41%, while the NASDAQ and S&P 500 saw gains of 0.54% and 0.22%, respectively, with consumer discretionary shares rising by 1.8%.

Key Economic Indicator: The ISM manufacturing PMI decreased to 48.7 in October, below market expectations, indicating a contraction in manufacturing activity.

Notable Stock Movements: Cipher Mining's shares surged 22% after a major lease agreement with Amazon, while uniQure's shares plummeted 50% following negative FDA feedback on its gene therapy.

Global Market Trends: European shares were mixed, with slight gains in the eurozone, while Asian markets closed higher, led by Hong Kong's Hang Seng index.

U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining 1%, while the Dow and S&P 500 also saw modest increases. Consumer discretionary shares rose by 1.8%, but utilities stocks fell by 0.8%.

ON Semiconductor Earnings Report: ON Semiconductor Corporation reported better-than-expected Q3 earnings of 63 cents per share, surpassing the analyst estimate of 59 cents, along with sales of $1.551 billion.

Significant Stock Movements: MSP Recovery, Inc. shares surged 255%, while Resolute Holdings Management, Inc. and Tharimmune, Inc. also saw significant gains. Conversely, uniQure N.V. shares dropped 59% following FDA feedback on its investigational gene therapy.

Global Market Trends: European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.2%, while Asian markets also closed higher, led by Hong Kong's Hang Seng and China's Shanghai Composite.